Literature DB >> 27078655

Bioinformatics analysis and expression of a novel protein ROP48 in Toxoplasma gondii.

Jian Zhou, Lin Wang, Aihua Zhou, Gang Lu, Qihang Li, Zhilin Wang, Meiyan Zhu, Huaiyu Zhou, Hua Cong, Shenyi He.   

Abstract

Toxoplasma gondii is an obligate intracellular apicomplexan parasite, and can infect warmblooded animals and humans all over the world. In the past years, ROP family genes encoding particular proteins of T. gondii had made a great contribution to toxoplasmosis. In this study, we used multiple bioinformatics approaches to predict the physical and chemical characteristics, transmembrane domain, epitope, and topological structure of the rhoptry protein 48 (ROP48). The results indicated that ROP48 protein was mainly located in the membrane and had several positive linear-B cell epitopes and Th-cell epitopes, which suggested that ROP48 is a potential DNA vaccine candidate against toxoplasmosis. Then the PCR product amplified from the ROP48 cDNA was inserted into a pEASY-T1 vector to build a recombinant cloning plasmid. After sequencing, ROP48 was subcloned into a eukaryotic expression plasmid pEGFP-C1 to obtain pEGFP-C1-ROP48 (pROP48). After identification by PCR and restriction enzyme digestion, the recombinant plasmid pROP48 was transfected into HEK 293-T cell and identified by RT-PCR. The results showed that the eukaryotic expression plasmid pROP48 was constructed and transfected to the cells of HEK 293-T successfully. Western blotting showed that the expressed proteins can be recognized by anti-STAg mouse sera.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27078655     DOI: 10.1515/ap-2016-0042

Source DB:  PubMed          Journal:  Acta Parasitol        ISSN: 1230-2821            Impact factor:   1.440


  8 in total

1.  Bioinformatics analysis of single and multi-hybrid epitopes of GRA-1, GRA-4, GRA-6 and GRA-7 proteins to improve DNA vaccine design against Toxoplasma gondii.

Authors:  Minoo Shaddel; Mansour Ebrahimi; Mohammad Reza Tabandeh
Journal:  J Parasit Dis       Date:  2018-04-17

2.  In-depth computational analysis of calcium-dependent protein kinase 3 of Toxoplasma gondii provides promising targets for vaccination.

Authors:  Hamidreza Majidiani; Shahrzad Soltani; Ali Dalir Ghaffari; Mohamad Sabaghan; Ali Taghipour; Masoud Foroutan
Journal:  Clin Exp Vaccine Res       Date:  2020-07-31

3.  SAG4 DNA and Peptide Vaccination Provides Partial Protection against T. gondii Infection in BALB/c Mice.

Authors:  Jian Zhou; Lin Wang
Journal:  Front Microbiol       Date:  2017-09-07       Impact factor: 5.640

4.  In silico analysis and expression of a new chimeric antigen as a vaccine candidate against cutaneous leishmaniasis.

Authors:  Leila Motamedpour; Abdolhossein Dalimi; Majid Pirestani; Fatemeh Ghaffarifar
Journal:  Iran J Basic Med Sci       Date:  2020-11       Impact factor: 2.699

5.  Bioinformatics analysis of calcium-dependent protein kinase 4 (CDPK4) as Toxoplasma gondii vaccine target.

Authors:  Masoud Foroutan; Shahrzad Soltani; Ali Taghipour; Ali Dalir Ghaffari; Hamidreza Majidiani; Mohamad Sabaghan
Journal:  BMC Res Notes       Date:  2021-02-06

6.  A Novel Chimeric Antigen as a Vaccine Candidate against Leishmania major: In silico Analysis.

Authors:  Niloofar Bavarsad Ahmadpour; Abdolhossein Dalimi; Majid Pirestani; Javid Sadraei
Journal:  Iran J Parasitol       Date:  2021 Apr-Jun       Impact factor: 1.012

7.  Immunoinformatic Analysis of Calcium-Dependent Protein Kinase 7 (CDPK7) Showed Potential Targets for Toxoplasma gondii Vaccine.

Authors:  Ali Taghipour; Sanaz Tavakoli; Mohamad Sabaghan; Masoud Foroutan; Hamidreza Majidiani; Shahrzad Soltani; Milad Badri; Ali Dalir Ghaffari; Sheyda Soltani
Journal:  J Parasitol Res       Date:  2021-07-08

8.  Immunoinformatic analysis of immunogenic B- and T-cell epitopes of MIC4 protein to designing a vaccine candidate against Toxoplasma gondii through an in-silico approach.

Authors:  Ali Dalir Ghaffari; Abdolhossein Dalimi; Fatemeh Ghaffarifar; Majid Pirestani; Hamidreza Majidiani
Journal:  Clin Exp Vaccine Res       Date:  2021-01-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.